PPL-1

Who is Dr. David L Morris?
Dr David L Morris, the discoverer of the anti-cancer effects of PPL-1 aka MPL, aka monepantel,, is one of Australia's leading oncological clinicians and oncology scientists. He is a professor in the faculty of medicine at the University of NSW in the St George and Sutherland Clinical School. He is also the largest shareholder in PharmAust (PAA). For more see:
https://med.unsw.edu.au/people/professor-david-morris
See also the executives on the board of PharmAust:
http://in.reuters.com/finance/stocks/companyOfficers?symbol=PAA.AX
--------------------------------------------------------
Final First Phase Clinical Trial Results of PPL-1 at Royal Adelaide Hospital:
During a year of scientific clinical trials conducted at Royal Adelaide Hospital with human patients, PPL-1 demonstrated biologic activity by the suppression of key cancer markers p70s6k and p-3E-BP1 when used to treat refractory tumours. PPL-1 also showed a low level of toxicity, an important advantage compared to many existing cancer treatments. See summary of the first phase clinical trial report results:
http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01674280
PharmAust has entered into a contract with GenScript for a pre-clinical validation process to greatly accelerate the phase 2 clinical trials of PPL-1.
http://www.asx.com.au/asxpdf/20151126/pdf/4339mlzvmxqchf.pdf
-------------------------------------------------------
Scientific research on PPL-1
http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=016059482

http://librarysearch.swinburne.edu....upid&dum=true&vl(freeText0)=monepantel cancer

http://librarysearch.swinburne.edu....upid&dum=true&vl(freeText0)=monepantel cancer